Cited by 662Liver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Kuchay, Mohammad Shafi, Krishan, Sonal, Mishra, Sunil Kumar, Farooqui, Khalid Jamal, Singh, Manish Kumar, Wasir, Jasjeet Singh, Bansal, Beena, Kaur, Parjeet, Jevalikar, Ganesh, Gill, Harmendeep Kaur, Choudhary, Narendra Singh, Mithal, Ambrish·2018·Diabetes Care

DOI 10.2337/dc18-0165

Open this paper in CoChat — free account

Abstract

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human liver fat are scarce. This study examined the effect of empagliflozin (an SGLT-2 inhibitor) on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) by using MRI-derived proton density fat fraction (MRI-PDFF). RESEARCH DESIGN AND METHODS Fifty patients with type 2 diabetes and NAFLD were randomly assigned to either the empagliflozin group (standard treatment for type 2 diabetes plus empagliflozin 10 mg daily) or the control group (standard treatment without empagliflozin) for 20 weeks. Change in liver fat was measured by MRI-PDFF. Secondary outcome measures were change in alanine transaminase (ALT), aspartate transaminase (AST), and γ-glutamyl transferase (GGT) levels. RESULTS When included in the standard treatment for type 2 diabetes, empagliflozin was significantly better at reducing liver fat (mean MRI-PDFF difference between the empagliflozin and control groups −4.0%; P < 0.0001). Compared with baseline, significant reduction was found in the end-of-treatment MRI-PDFF for the empagliflozin group (16.2% to 11.3%; P < 0.0001) and a nonsignificant change was found in the control group (16.4% to 15.5%; P = 0.057). The two groups showed a significant difference for change in serum ALT level (P = 0.005) and nonsignificant differences for AST (P = 0.212) and GGT (P = 0.057) levels. CONCLUSIONS When included in the standard treatment for type 2 diabetes, empagliflozin reduces liver fat and improves ALT levels in patients with type 2 diabetes and NAFLD.

Integrity signals

Registry

Crossref · 10.2337/dc18-0165

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values
MOFRAD, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,199

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 657

Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 34
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
Sun, L., Deng, C., Gu, Y., He, Y., Yang, L., & Shi, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101876 · Cited by 31
Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 35
Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?
Binet, Q., Loumaye, A., Preumont, V., Thissen, J., Hermans, M. P., & Lanthier, N. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.9775 · Cited by 35
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 32
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 34
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 31
Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial (MIRAD trial)
Johansen, M. L., Schou, M., Rossignol, P., Holm, M. R., Rasmussen, J., Brandt, N., Frandsen, M. N., Chabanova, E., Dela, F., Faber, J. O., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13809 · Cited by 29
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Zhang, E., Zhao, Y., & Hu, H. (2021) · Hepatology Communications · doi:10.1002/hep4.1611 · Cited by 30
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
Handelsman, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01054-w · Cited by 30
Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials
Simental-Mendía, M. A., Sánchez‐García, A., Rodríguez-Ramírez, M., & Simental‐Mendía, L. E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105319 · Cited by 28
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 27
Self-citation
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 31
Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease
Lee, S. J., & Kim, S. U. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1608820 · Cited by 26
Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
Sinha, B., Datta, D., & Ghosal, S. (2020) · JGH Open · doi:10.1002/jgh3.12473 · Cited by 26
Hypoglycemic effects of space‐induced Lactobacillus plantarum SS18‐5 on type 2 diabetes in a rat model
Yang, F., Wang, J., Zhang, H., Xie, Y., Jin, J., Liu, H., Pang, X., & Hao, H. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13899 · Cited by 27
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence
Yabiku, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.768850 · Cited by 27
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 26
Updates in Metabolic Dysfunction‐Associated Fatty Liver Disease (MAFLD) in Children
Rupasinghe, K., Hind, J. M., & Hegarty, R. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003919 · Cited by 30
SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Gharaibeh, N. E., Rahhal, M.-N., Rahimi, L., & Ismail‐Beigi, F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s212715 · Cited by 27
2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., Neto, J. M. D. A., & Bertoluci, M. C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01259-2 · Cited by 30
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 30
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Chrysavgis, L., Papatheodoridi, A., Chatzigeorgiou, A., & Cholongitas, Ε. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15202 · Cited by 26
Novel glucose-lowering drugs for non-alcoholic fatty liver disease
Fu, Z., Cai, X., Yang, W., Zhao, M.-M., Li, R., & Li, Y. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i1.84 · Cited by 26
The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
Mo, M.-Q., Huang, Z., Liang, Y., Liao, Y., & Xia, N. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.017 · Cited by 26
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial
Horibe, K., Morino, K., Miyazawa, I., Tanaka‐Mizuno, S., Kondo, K., Sato, D., Ohashi, N., Ida, S., Yanagimachi, T., Yoshimura, M., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109781 · Cited by 26
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Kim, J., & Kwon, H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0377 · Cited by 31
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 28
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
Pennisi, G., Celsa, C., Spatola, F., Dallio, M., Federico, A., & Petta, S. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16224334 · Cited by 25
An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist
Puri, P., & Kotwal, N. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.09.010 · Cited by 29
Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats
Asada, S., Kaji, K., Nishimura, N., Koizumi, A., Matsuda, T., Tanaka, M., Yorioka, N., Sato, S., Kitagawa, K., Namisaki, T., et al. (2024) · Cells · doi:10.3390/cells13060538 · Cited by 24
Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management
Berković, M. C., Virović-Jukić, L., Bilić-Čurčić, I., & Mrzljak, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2740 · Cited by 24
Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials
Lee, K. W., Devaraj, N. K., Ching, S. M., Veettil, S. K., Hoo, F. K., Deuraseh, I., & Soo, M. J. (2021) · Oman Medical Journal · doi:10.5001/omj.2021.62 · Cited by 24
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 25
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis
Sakuma, T., Nakamura, M., Chiba, T., Iwanaga, T., Kan, M., Kojima, R., Ao, J., Ma, Y., Unozawa, H., Fujita, N., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00807-6 · Cited by 24
Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
Mao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 25
Exploring the links between types 2 diabetes and liver‐related complications: A comprehensive review
Sanchez, L. O., Chen, Y., Lassailly, G., & Qi, X. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12508 · Cited by 26
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Chen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 24
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease
Song, T., Chen, S., Zhao, H., Wang, F., Song, H., Tian, D., Yang, Q., & Qi, L. (2021) · Hepatology Research · doi:10.1111/hepr.13645 · Cited by 23
Interaction of inflammation and portal hypertension in cirrhosis progression
Costa, D., Trebicka, J., Ripoll, C., Moreau, R., Jalan, R., & Reiberger, T. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01107-2 · Cited by 27
Effects of sodium‐glucose co‐transporter‐2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: A multi‐institutional cohort study
Shao, S., Chang, K., Chien, R., Lin, S., Hung, M., Chan, Y., Yang, Y. K., & Lai, E. C. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13875 · Cited by 22
Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials
Ayesh, H., Beran, A., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12102328 · Cited by 23
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Jung, C., & Mok, J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.18 · Cited by 22
Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?
Katsiki, N., Dimitriadis, G., & Mikhailidis, D. P. (2019) · Angiology · doi:10.1177/0003319719848204 · Cited by 22
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
Vincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 21
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
Ma, Y., Kan, C., Qiu, H., Liu, Y., Hou, N., Han, F., Shi, J., & Sun, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.793586 · Cited by 24
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Li, H., Hou, Y., Xin, W., Ding, L., Yang, Y., Zhang, Y., Wu, W., Wang, Z., & Ding, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107647 · Cited by 22
Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020) · Diabetic Medicine · doi:10.1111/dme.14356 · Cited by 21
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Euh, W., Lim, S. K., & Kim, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613389 · Cited by 23
Anti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 21
Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease
Yen, F., Hsu, C., Wei, J. C., Hou, M., & Hwu, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.839456 · Cited by 20
A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes
Doustmohammadian, A., Nezhadisalami, A., Tameshkel, F. S., Motamed, N., Maadi, M., Farahmand, M., Sohrabi, M., Clark, C. C. T., Ajdarkosh, H., Faraji, A. H., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.937554 · Cited by 21
The emerging significance of mitochondrial targeted strategies in NAFLD treatment
Zhang, T., Nie, Y., & Wang, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121943 · Cited by 21
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
Lajara, R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1670017 · Cited by 21
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
Marjot, T., Green, C., Charlton, C. A., Cornfield, T., Hazlehurst, J., Moolla, A., White, S. J., Francis, J. M., Neubauer, S., Cobbold, J., et al. (2019) · JGH Open · doi:10.1002/jgh3.12274 · Cited by 21
The molecular basis for current targets of NASH therapies
Qureshi, K., & Neuschwander‐Tetri, B. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1703949 · Cited by 23
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 24
The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
Pokharel, A., Sudhamshu, K. C., Thapa, P., Karki, N., Shrestha, R., Jaishi, B., & Paudel, M. S. (2021) · Cureus · doi:10.7759/cureus.16687 · Cited by 22
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats
Lv, Q., Le, L., Xiang, J., Jiang, B., Chen, S., & Xiao, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00111 · Cited by 20
Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial
Sato, M., Akamatsu, M., Shima, T., Ikegami, T., Yanase, M., Mikami, S., Imamura, J., Nakatsuka, T., Tateishi, R., Yamauchi, N., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002143 · Cited by 20
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
Bea, S., Jeong, H. E., Filion, K. B., Yu, O. H., Cho, Y. M., Lee, B. H., Chang, Y., Byrne, C. D., & Shin, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.49856 · Cited by 22
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, M. S., Farooqui, K. J., Mishra, S. K., & Mithal, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_479 · Cited by 21
Self-citation
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 22
A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 22
Therapies for non-alcoholic fatty liver disease: A 2022 update
Shen, K., Singh, A. D., Esfeh, J. M., & Wakim-Fleming, J. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i9.1718 · Cited by 23
NAFLD as the metabolic hallmark of obesity
Rojano‐Toimil, A., Sena, E., Manzano-Núñez, R., Pericàs, J. M., & Ciudin, A. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03139-x · Cited by 22
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 22
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 23
Emerging therapies for MASLD and their impact on plasma lipids
Nguyen, M., Asgharpour, A., Dixon, D. L., Sanyal, A. J., & Mehta, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100638 · Cited by 20
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Kalra, S., Shetty, K., Nagarajan, V. B., & Ved, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00789-y · Cited by 19
Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
Yasin, A., Nguyen, M., Sidhu, A., Majety, P., Spitz, J. A., Asgharpour, A., Siddiqui, M. S., Sperling, L. S., Quyyumi, A. A., & Mehta, A. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111650 · Cited by 19
When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
Rojano‐Toimil, A., Rivera‐Esteban, J., Manzano-Núñez, R., Bañares, J., Selva, D. M., Gabriel-Medina, P., Ferrer, R., Pericàs, J. M., & Ciudin, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123286 · Cited by 20
The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial
Shojaei, F., Erfanifar, A., Kalbasi, S., Nikpour, S., & Gachkar, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01882-8 · Cited by 17
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease
Amin, M. A., Sadik, N. A., Saad, H. A., Fawzy, M., & Elsheimy, H. A. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03902-w · Cited by 21
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
Nakamura, I., Maegawa, H., Tobe, K., & Uno, S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0895-1 · Cited by 17
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
Shin, Y., Moon, J. H., Chin, H. J., Ferrannini, E., & Lim, S. K. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.329 · Cited by 17
Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Kalogirou, M., Patoulias, D., Haidich, A., Akriviadis, E. A., & Sinakos, E. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.10.012 · Cited by 17
SGLT2 inhibitors in heart failure with reduced ejection fraction
Das, U. S., Paul, A., & Banerjee, S. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00218-w · Cited by 22
Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial
Agrinier, A.-L., Morissette, A., Daoust, L., Gignac, T., Marois, J., Varin, T. V., Pilon, G., Larose, É., Gagnon, C., Desjardins, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101682 · Cited by 20
Non‑alcoholic fatty liver disease: A major challenge in type�2 diabetes mellitus (Review)
Bică, C., Sandu, C., Suceveanu, A., Sarbu, E., Stoica, R. A., Gherghiceanu, F., Bohîlțea, R. E., Ștefan, S., & Stoian, A. P. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8882 · Cited by 17
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hanif, H., Khan, M. M., Ali, M. J., Shah, P. A., Satiya, J., Lau, D., & Aslam, A. (2020) · Microorganisms · doi:10.3390/microorganisms8101526 · Cited by 17
Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
Yoshino, K., Hosooka, T., Shinohara, M., Aoki, C., Hosokawa, Y., Imamori, M., & Ogawa, W. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.04.012 · Cited by 17
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 20
Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 18
The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial
Abdallah, M. S., Eldeen, A. H., Tantawy, S. S., & Mostafa, T. M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174295 · Cited by 16
Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial
Lin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302155 · Cited by 17
Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges
Luo, S., Zheng, M., Wong, V. W., & Yeung, S. L. A. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100114 · Cited by 17
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 16
Relationship between circulating miR-132 and non-alcoholic fatty liver disease in a Chinese population
Zong, Y., Yan, J. Y., Jin, L., Xu, B., He, Z., Zhang, R., Hu, C., & Jia, W. (2020) · Hereditas · doi:10.1186/s41065-020-00136-y · Cited by 16
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus
Shinozaki, S., Tahara, T., Lefor, A. K., & Ogura, M. (2020) · The Journal of Medical Investigation · doi:10.2152/jmi.67.280 · Cited by 16
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
Seino, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01014-0 · Cited by 16
Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
Ding, C., Tang, Y., Zhu, W., Huang, P., Lian, P., Ran, J., & Huang, X. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01830-7 · Cited by 16
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Gallo, S., Calle, R. A., Terra, S. G., Pong, A., Tarasenko, L. C., & Raji, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00867-1 · Cited by 16
NAFLD and NASH: The Metabolically Diseased Liver
Armandi, A., & Schattenberg, J. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_561 · Cited by 16
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
Yang, Z., Tian, R., Zhang, X., Cai, J., She, Z., & Li, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1120085 · Cited by 16
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors
Khanmohammadi, S., Ramos‐Molina, B., & Kuchay, M. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102788 · Cited by 15
Self-citation

Authors: Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., Choudhary, N. S., & Mithal, A.
Affiliations: Medanta The Medicity (IN)
Corresponding author: Kuchay, Mohammad Shafi
ORCID: Kuchay, Mohammad Shafi
Mishra, Sunil Kumar
Singh, Manish Kumar
Bansal, Beena
Kaur, Parjeet
Jevalikar, Ganesh
Choudhary, Narendra Singh
Mithal, Ambrish
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2018-06-12
Volume: 41
Issue: 8
Pages: 1801-1808
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc18-0165
OpenAlex: W2808615577
Cited by: 662
References: 40
Citations by year: 2026: 81 · 2025: 98 · 2024: 73 · 2023: 86 · 2022: 85 · 2021: 78 · 2020: 88 · 2019: 52 · 2018: 18
FWCI: 46.08
Type: journal article
Language: en
Open access: closed
Licence: www.diabetesjournals.org/content/license (vor, 38 d)
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: Endocrine and Diabetes Foundation, India
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: empagliflozin, SGLT2 inhibitors, liver fat, non-alcoholic fatty liver disease, type 2 diabetes, proton density fat fraction, alanine aminotransferase, liver enzymes
MeSH terms: Adipose Tissue, Adult, Alanine Transaminase, Aspartate Aminotransferases, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Treatment Outcome, Adiposity, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks